3.23
Precedente Chiudi:
$3.20
Aprire:
$3.21
Volume 24 ore:
429.02K
Relative Volume:
0.61
Capitalizzazione di mercato:
$320.35M
Reddito:
$69.56M
Utile/perdita netta:
$-240.05M
Rapporto P/E:
-1.0949
EPS:
-2.95
Flusso di cassa netto:
$-121.90M
1 W Prestazione:
+3.86%
1M Prestazione:
+13.33%
6M Prestazione:
+82.49%
1 anno Prestazione:
-13.40%
Adc Therapeutics Sa Stock (ADCT) Company Profile
Nome
Adc Therapeutics Sa
Settore
Industria
Telefono
41 21 653 02 00
Indirizzo
BIOPOLE, EPALINGES
Confronta ADCT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ADCT
Adc Therapeutics Sa
|
3.23 | 359.23M | 69.56M | -240.05M | -121.90M | -2.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-08 | Iniziato | Stephens | Overweight |
2024-05-30 | Iniziato | Cantor Fitzgerald | Overweight |
2024-03-28 | Iniziato | Guggenheim | Buy |
2023-08-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
2023-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
2022-12-06 | Iniziato | CapitalOne | Overweight |
2022-11-09 | Downgrade | BofA Securities | Buy → Neutral |
2022-09-21 | Iniziato | JP Morgan | Overweight |
2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2021-11-09 | Iniziato | Wolfe Research | Outperform |
2021-08-17 | Ripresa | Jefferies | Buy |
2021-08-09 | Iniziato | RBC Capital Mkts | Outperform |
2021-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
2020-12-03 | Iniziato | Stifel | Hold |
2020-10-29 | Iniziato | H.C. Wainwright | Buy |
2020-06-09 | Iniziato | BofA/Merrill | Buy |
2020-06-09 | Iniziato | Cowen | Outperform |
Mostra tutto
Adc Therapeutics Sa Borsa (ADCT) Ultime notizie
What analysts say about ADC Therapeutics SA stockExceptional market performance - PrintWeekIndia
Is ADC Therapeutics SA a good long term investmentAccelerated wealth building - Autocar Professional
What drives ADC Therapeutics SA stock priceBreakout stock performance - jammulinksnews.com
ADC Therapeutics SA Stock Analysis and ForecastExplosive portfolio gains - jammulinksnews.com
ADC Therapeutics’ LOTIS-10 Study: A Potential Game-Changer in Lymphoma Treatment - TipRanks
What makes ADC Therapeutics SA stock price move sharplyCapital Growth Picks - Newser
Why ADC Therapeutics SA stock attracts strong analyst attentionFree Market Sentiment Analysis - Newser
How ADC Therapeutics SA stock performs during market volatilityFree Exclusive Stock Market Insights - Newser
ADC Therapeutics (NYSE:ADCT) Shares Down 4.2%What's Next? - MarketBeat
Adc Therapeutics Sa shares fall 1.88% after-hours as Sonnet Biotherapeutics, Inc. announces $888 million funding. - AInvest
ADC Therapeutics (NYSE:ADCT) Shares Down 4.2% – Here’s Why - Defense World
ADC Therapeutics announces $100M private financing - MSN
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan - The Malaysian Reserve
ADC Therapeutics (ADCT) Files Prospectus for Share Sale - GuruFocus
ADCT SEC FilingsAdc Therapeutics Sa 10-K, 10-Q, 8-K Forms - Stock Titan
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? - Weekly Voice
ADC reports data from lymphoma trial, streamlines operations - MSN
ADC Therapeutics (NYSE:ADCT) Stock Rating Upgraded by Royal Bank Of Canada - MarketBeat
ADC Therapeutics (ADCT) Price Target Lowered by RBC Capital | AD - GuruFocus
ADC Therapeutics price target lowered to $5 at RBC on growth outlook - Investing.com
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes - Quantisnow
Adc Therapeutics SA (NYSE: ADCT) Continues Its Downward Trend - Stocksregister
ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma - marketscreener.com
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial By Investing.com - Investing.com Nigeria
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial - Investing.com Australia
Breakthrough Lymphoma Treatment: ZYNLONTA Shows 85% Response Rate with 27-Month Durability in Latest Trial - Stock Titan
Switzerland: ADC Therapeutics raises US$100m from PIPE financing - Investors in Healthcare
Guggenheim Reaffirms Buy Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics (NYSE:ADCT) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
Analysts Set Expectations for ADCT FY2026 Earnings - MarketBeat
Guggenheim Raises Price Target for ADC Therapeutics (ADCT) | ADCT Stock News - GuruFocus
ADC Therapeutics (ADCT) Price Target Raised Amid Strategic Moves - GuruFocus
ADC Therapeutics (ADCT) Secures $100M in PIPE Financing to Boost ZYNLONTA Development - GuruFocus
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
Adc Therapeutics Sa Azioni (ADCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):